Phase II study results of lurbinectedin in
progressive mesothelioma will be presented in an oral session at ESMO 2019

On September 23, 2019 PharmaMar is a biopharmaceutical company reported that During the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, to be held from September 27th to October 1 st in Barcelona, the recent results of the lurbinectedin trial for the treatment of progressive malignant pleural mesothelioma, carried out by SAKK (Swiss Group for Clinical Cancer Research) in collaboration with PharmaMar (MSE:PHM), will be presented (Press release, PharmaMar, SEP 23, 2019, View Source [SID1234539709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will be entitled "SAKK 17/16: Lurbinectedin as second or third line palliative chemotherapy in pleural malignant mesothelioma (MPM): A multicenter, single-arm Phase II trial". During this conference, the primary results will be shown from a single arm, multicenter, Phase II trial, which has enrolled 42 patients with progressive malignant pleural mesothelioma, which met its primary endpoint of PFS at 12 weeks.

Malignant mesothelioma is a rare tumor, arising from the mesothelial cells of the pleural, peritoneal or pericardial lining, and is often associated with exposure to asbestos, usually with a very poor prognosis at the time of diagnosis, being pleural mesothelioma the most frequent location. There is currently no cure for most malignant mesotheliomas. Therefore, the goal of current cancer treatments (surgery, radiation therapy, and chemotherapy) is to reduce or eliminate symptoms, as well as to prolong progression-free survival (PFS) and/or overall survival (OS). It is estimated that the incidence of this type of cancer may increase in the coming years, after the exposure to asbestos. It usually takes a long time before a malignant mesothelioma forms.

Trabectedin 2 In addition, the data obtained in several clinical studies carried out with trabectedin, evaluating new combinations of trabectedin for the treatment of soft tissue sarcoma, ovarian cancer and different solid tumors will be presented. Among them, data from a multicenter Phase II study of trabectedin in combination with a low dose of radiotherapy conducted by Sarcoma Research Groups in Spain, France and Italy, will be presented.

The studies presented at the ESMO (Free ESMO Whitepaper) 2019 congress are available at: View Source Highlighted studies at ESMO (Free ESMO Whitepaper) 2019 Lurbinectedin  Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma) Oral presentation-30.09.2019, 10:15-11:45, Pamplona Auditorium (Hall 2) Autor principal: Yannis Metaxas (Chur, Switzerland)  Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors Poster Display session-28.09.2019, 12:00-13:00, Poster Area (Hall 4) Autor principal: Santiago Ponce Yondelis (trabectedin)  Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups Poster Discussion – Sarcoma. 28.09.2019, 15:00-16:00, en Malaga Auditorium (Hall 5) Autor principal: J Martin-Broto (Sevilla)  Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma Poster Display session. 28.09.2019, 12:00-13:00, Poster Area (Hall 4). Autor principal: David S. Moura, PhD. 3  Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies Poster-30.09.2019, 12:00-13:00, en el Hall A3-Poster Area (Hall 4) Autor principal: S Christoph E. Heilig, Germany.  Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006) Poster-29.09.2019, 12:00-13:00, Poster Area (Hall 4). Autor principal: Bradley J Monk, USA.

Legal warning This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.